Inovio Pharmaceuticals Inc logo

INO

Inovio Pharmaceuticals Inc

$2.48

Earnings Summary

Revenue
$0.2Mn
Net Profits
$-79.07Mn
Net Profit Margins
-39720.77%

Highlights

Revenue:

Inovio Pharmaceuticals Inc’s revenue fell -46.36% since last year same period to $0.2Mn in the Q1 2022. On a quarterly growth basis, Inovio Pharmaceuticals Inc has generated -76.28% fall in its revenue since last 3-months.

Net Profits:

Inovio Pharmaceuticals Inc’s net profit fell -45.35% since last year same period to $-79.07Mn in the Q1 2022. On a quarterly growth basis, Inovio Pharmaceuticals Inc has generated 26.06% jump in its net profits since last 3-months.

Net Profit Margins:

Inovio Pharmaceuticals Inc’s net profit margin fell -170.97% since last year same period to -39720.77% in the Q1 2022. On a quarterly growth basis, Inovio Pharmaceuticals Inc has generated -211.65% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Inovio Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.31
EPS Estimate Current Year
-0.31

Highlights

EPS Estimate Current Quarter:

Inovio Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.31 - a 8.82% jump from last quarter’s estimates.

EPS Estimate Current Year:

Inovio Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.31.

Key Ratios

Key ratios of the Inovio Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.36
Return on Assets (ROA)
-0.41
Return on Equity (ROE)
-0.88
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Inovio Pharmaceuticals Inc’s earning per share (EPS) fell -33.33% since last year same period to -0.36 in the Q1 2022. This indicates that the Inovio Pharmaceuticals Inc has generated -33.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inovio Pharmaceuticals Inc’s return on assets (ROA) stands at -0.41.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inovio Pharmaceuticals Inc’s return on equity (ROE) stands at -0.88.

Dividend Per Share (DPS):

Inovio Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.34
-0.36
-5.88%

Company Information

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO's lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards 'W' designation recognizing companies with more than 20% women on their board of directors.

Organisation
Inovio Pharmaceuticals Inc
Headquarters
San Diego, California, US
Employees
262
Industry
Health Technology
CEO
Jong Kim